Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist

Endocrinology

Volumn 147, Issue 10, 2006, Pages 4664-4673

  Strowski, Mathias Z ^a   Cashen, Doreen E ^b   Birzin, Elizabeth T ^b   Yang, Lihu ^b   Singh, Vandana ^a   Jacks, Thomas M ^b   Nowak, Krzysztof W ^d   Rohrer, Susan P ^b   Patchett, Arthur A ^b   Smith, Roy G ^c   Schaeffer, James M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; GLUCAGON; GLUCOSE; INSULIN; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2 AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL ISOLATION; DIET RESTRICTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; GLUCOSE BLOOD LEVEL; HORMONE INHIBITION; HORMONE RELEASE; IC 50; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOGS; GLUCAGON; GROWTH HORMONE; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; RATS; RECEPTORS, SOMATOSTATIN;

EID: 33748744450     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0274     Document Type: Article

References (56)

1. Cherrington AD, Williams PE, Shulman GI, Lacy WW 1981 Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes 30:180-187
2. Magnusson I, Rothman DL, Gerard DP, Katz LD, Shulman GI 1995 Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 44:185-189
3. Weir GC, Bonner-Weir S 1990 Islets of Langerhans: the puzzle of intraislet interactions and their relevance to diabetes. J Clin Invest 85:983-987
4. Samols E, Bonner-Weir S, Weir GC 1986 Intra-islet insulin-glucagon- somatostatin relationships. Clin Endocrinol Metab 15:33-58
5. Klaff LJ, Taborsky Jr GJ 1987 Pancreatic somatostatin is a mediator of glucagon inhibition by hyperglycemia. Diabetes 36:592-596
6. Stagner JI, Samols E 1992 The vascular order of islet cellular perfusion in the human pancreas. Diabetes 41:93-97
7. Ensinck JW, Vogel RE, Laschansky EC, Koerker DJ, Prigeon RL, Kahn SE, D'Alessio DA 1997 Endogenous somatostatin-28 modulates postprandial insulin secretion. Immunoneutralization studies in baboons. J Clin Invest 100:2295-2302
8. Greenbaum CJ, Havel PJ, Taborsky Jr GJ, Klaff LJ 1991 Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. J Clin Invest 88:767-773
9. Taborsky Jr GJ 1983 Evidence of a paracrine role for pancreatic somatostatin in vivo. Am J Physiol 245:E598-E603.
10. Shah P, Basu A, Basu R, Rizza R 1999 Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277:E283-E290
11. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB 1987 Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106-110
12. Ohneda A, Watanabe K, Horigome K, Sakai T, Kai Y, Oikawa S 1978 Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. J Clin Endocrinol Metab 46:504-510
13. Dinneen S, Alzaid A, Turk D, Rizza R 1995 Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343
14. Unger RH 1975 Letter: Glucagon in pathogenesis of diabetes. Lancet 1:1036-1042
15. Unger RH, Orci L 1975 The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16
16. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ 1994 Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985-993
17. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, Demarest KT 2004 Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53:410-417
18. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB 1995 The somatostatin receptor family. Life Sci 57:1249-1265
19. Patel YC 1999 Somatostatin and its receptor family. Front Neuroendocrinol 20:157-198
20. Lunetta M, Di Mauro M, Le Moli R, Nicoletti F 1997 Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients. Diabetes Res Clin Pract 38:81-89
21. Christensen SE, Hansen AP, Lundbaek K 1978 Somatostatin in maturity-onset diabetes. Diabetes 27:1013-1019
22. Williams G, Fuessl HS, Burrin JM, Chilvers E, Bloom SR 1988 Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus. Horm Metab Res 20:168-170
23. Guillemin R, Gerich JE 1976 Somatostatin: physiological and clinical significance. Annu Rev Med 27:379-388
24. Mitra SW, Mezey E, Hunyady B, Chamberlain L, Hayes E, Foor F, Wang Y, Schonbrunn A, Schaeffer JM 1999 Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic β-cells. Endocrinology 140:3790-3796
25. Hunyady B, Hipkin RW, Schonbrunn A, Mezey E 1997 Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas. Endocrinology 138:2632-2635
26. Cejvan K, Coy DH, Efendic S 2003 Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats. Diabetes 52:1176-1181
27. Rossowski WJ, Coy DH 1994 Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. Biochem Biophys Res Commun 205:341-346
28. Strowski MZ, Parmar RM, Blake AD, Schaeffer JM 2000 Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141:111-117
29. Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, Gopal-Truter S, Fisher JK, Schaeffer JM, Blake AD, Zhang BB, Wilkinson HA 2003 Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol 17:93-106
30. Yang L, Berk SC, Rohrer SP, Mosley RT, Guo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC, Mitra SW, Parmar RM, Cheng K, Wu TJ, Butler BS, Foor F, Pasternak A, Pan Y, Silva M, Freidinger RM, Smith RG, Chapman K, Schaeffer JM, Patchett AA 1998 Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci USA 95:10836-10841
31. Stearns SB, Benzo CA 1978 Glucagon and insulin relationships in genetically diabetic (db/db) and in streptozotocin-induced diabetic mice. Horm Metab Res 10:20-23
32. Dunbar JC, Walsh MF 1980 Glucagon and insulin secretion by islets of lean and obese (ob/ob) mice. Horm Metab Res 12:39-40
33. Coleman DL, Hummel KP 1967 Studies with the mutation, diabetes, in the mouse. Diabetologia 3:238-248
34. Coleman DL 1978 Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14:141-148
35. Hummel KP, Dickie MM, Coleman DL 1966 Diabetes, a new mutation in the mouse. Science 153:1127-1128
36. Zheng H, Bailey A, Jiang MH, Honda K, Chen HY, Trumbauer ME, Van der Ploeg LH, Schaeffer JM, Leng G, Smith RG 1997 Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons. Mol Endocrinol 11:1709-1717
37. Jacks T, Hickey G, Judith F, Taylor J, Chen H, Krupa D, Feeney W, Schoen W, Ok D, Fisher M 1994 Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J Endocrinol 143:399-406.
38. Kaku K, Fiedorek Jr FT, Province M, Permutt MA 1988 Genetic analysis of glucose tolerance in inbred mouse strains. Evidence for polygenic control. Diabetes 37:707-713
39. Moller N, Jorgensen JO, Moller J, Orskov L, Ovesen P, Schmitz O, Christiansen JS, Orskov H 1995 Metabolic effects of growth hormone in humans. Metabolism 44:33-36
40. Berk SC, Rohrer SP, Degrado SJ, Birzin ET, Mosley RT, Hutchins SM, Pasternak A, Schaeffer JM, Underwood DJ, Chapman KT 1999 A combinatorial approach toward the discovery of non-peptide, subtype-selective somatostatin receptor ligands. J Comb Chem 1:388-396
41. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM 1998 Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282:737-740
42. Tulipano G, Soldi D, Bagnasco M, Culler MD, Taylor JE, Cocchi D, Giustina A2002 Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143:1218-1224
43. Moldovan S, Atiya A, Adrian TE, Kleinman RM, Lloyd K, Olthoff K, Imagawa D, Shevlin L, Coy D, Walsh J 1995 Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. J Surg Res 59:85-90.
44. Petersen KF, Sullivan JT 2001 Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024
45. Candrina R, Giustina G 1988 Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients. J Endocrinol Invest 11:501-507
46. Candrina R, Coppini A, Graffeo M, Zuccato F, Giustina G 1987 SMS 201-995 improves glucose tolerance in insulin-treated type II diabetic patients. Diabetes Care 10:534-535
47. Giustina A, Girelli A, Buffoli MG, Cimino A, Legati F, Valentini U, Giustina G 1991 Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. Diabetes Res Clin Pract 14:47-54
48. Davis SN, Goldstein RE, Jacobs J, Price L, Wolfe R, Cherrington AD 1993 The effects of differing insulin levels on the hormonal and metabolic response to equivalent hypoglycemia in normal humans. Diabetes 42:263-272
49. Davis SN, Cherrington AD, Goldstein RE, Jacobs J, Price L 1993 Effects of insulin on the counterregulatory response to equivalent hypoglycemia in normal females. Am J Physiol 265:E680-E689
50. Hofland LJ, van der HJ, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654
51. Ben Shlomo A, Wawrowsky KA, Proekt I, Wolkenfeld NM, Ren SG, Taylor J, Culler MD, Melmed S 2005 Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion. J Biol Chem 280:24011-24021
52. Gotoh M, Iguchi A, Kakumu S, Hirooka Y, Smythe GA 2001 Central suppressive effect of octreotide on the hyperglycemic response to 2-deoxy-D-glucose injection or cold-swim stress in awake rats: possible mediation role of hypothalamic noradrenergic drive. Brain Res 895:146-152
53. Flattem N, Igawa K, Shiota M, Emshwiller MG, Neal DW, Cherrington AD 2001 α- and β-cell responses to small changes in plasma glucose in the conscious dog. Diabetes 50:367-375
54. Hojlund K, Wildner-Christensen M, Eshoj O, Skjaerbaek C, Holst JJ, Koldkjaer O, Moller JD, Beck-Nielsen H 2001 Reference intervals for glucose, β-cell polypeptides, and counterregulatory factors during prolonged fasting. Am J Physiol Endocrinol Metab 280:E50-E58
55. Weckbecker G, Briner U, Lewis I, Bruns C 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143:4123-4130
56. Unger RH 1976 The Banting Memorial Lecture 1975. Diabetes and the α cell. Diabetes 25:136-151